Ximelagatran, un nuevo inhibidor oral directo de la trombina. (Inglés)

"Ximelagatran, un nuevo inhibidor oral directo de la trombina, para la prevención de procesos tromboembólicos venosos en la cirugía mayor ortopédica de elección. Eficacia, Seguridad y consideraciones anestésicas."

N. Rosencher


The oral direct thrombin inhibitor ximelagatran shows great promise for prevention of venous thromboembolic events following major elective orthopaedic surgery. Its consistent and predictable pharmacokinetics and pharmacodynamics across a wide range of patient populations allow administration with fixed dosing and with no coagulation monitoring. In orthopaedic surgery clinical trials, ximelagatran was effective and well tolerated compared with standard therapy, with dose and timing relative to surgery important factors in determining its optimal profile. In European trials, an initial 3-mg postoperative dose of subcutaneous melagatran, the active form of ximelagatran, followed by oral ximelagatran 24 mg twice daily achieved similar efficacy and safety to enoxaparin. Although the risk of spinal haematoma following neuraxial anaesthesia is rare, it is increased by the concomitant use of anticoagulants. In orthopaedic surgery trials with ximelagatran to date, complications such as spinal haematoma have not been reported. The pharmacokinetic profile of ximelagatran suggests that concurrent use with neuraxial anaesthesia should require no further precautions than those currently necessary with low-molecular-weight heparin.

Jounal of the Association of Anaesthetist of Great Britain and Ireland. Volume 59: Issue 8. Page range: 803 - 810.

Introduce tu búsqueda en el cajetín para encontrar contenido.

Ir al contenido